Making the switch: a retrospective case series of our departmental experience of biosimilar medications
暂无分享,去创建一个
[1] K. Reynolds,et al. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review , 2020, Expert opinion on drug safety.
[2] W. Liao,et al. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis , 2020, American Journal of Clinical Dermatology.
[3] C. Prinsen,et al. Clinical visible signs of disease activity in vitiligo: a systematic review and meta‐analysis , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] L. Puig,et al. Biosimilars for the treatment of psoriasis , 2019, Expert opinion on biological therapy.
[5] G. Girolomoni,et al. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience , 2019, The Journal of dermatological treatment.
[6] T. Torres,et al. Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients. , 2018, Acta medica portuguesa.